Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet membrane protein CD36.

H Ikeda1

  • 1Department of Laboratory Medicine, Asahikawa Medical College, Japan.

[Hokkaido Igaku Zasshi] the Hokkaido Journal of Medical Science
|July 1, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Purification and characterization of DNA topoisomerase IV in Escherichia coli.

The Journal of biological chemistry·1992
Same author

Prognostic factor of telecobalt therapy for early glottic carcinoma.

Cancer·1992
Same author

[Adult T-cell leukemia with various pulmonary complications].

Nihon Kyobu Shikkan Gakkai zasshi·1992
Same author

Sulfur amino acid levels and related enzyme activities in various brain regions (and other tissues) in normal mice and rolling mice Nagoya.

Acta medica Okayama·1992
Same author

[Adult T-cell leukemia/lymphoma, histologically presenting Ki-1 positive anaplastic large cell lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology·1992
Same author

Phase I/II study of high-dose rate interstitial radiotherapy for head and neck cancer.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·1992

Platelet CD36 (GPIV) is crucial for arachidonic acid uptake, essential for platelet aggregation. CD36 deficiency impairs this process, particularly in low arachidonic acid conditions, impacting platelet function.

Area of Science:

  • Hematology
  • Molecular Biology
  • Immunology

Background:

  • CD36, also known as GPIV, is a major platelet glycoprotein with diverse ligand-binding capabilities in vitro.
  • Its precise in vivo functions, particularly in platelet aggregation, remain incompletely understood.
  • CD36 deficiency provides a unique model to elucidate its physiological roles.

Purpose of the Study:

  • To investigate the in vivo role of CD36 in platelet aggregation, specifically its contribution to arachidonic acid uptake.
  • To analyze the genetic basis of CD36 deficiency and its impact on protein expression and function.

Main Methods:

  • Comparative analysis of platelet aggregation in CD36-deficient and normal individuals under calcium-deficient conditions.
  • Assessment of calcium influx and arachidonic acid uptake in response to agonists.

Related Experiment Videos

  • Genetic analysis of CD36 cDNA and genomic DNA to identify mutations and their effects on protein expression.

    • Main Results:

    • CD36-deficient platelets show delayed and reduced irreversible aggregation in a calcium-deficient state.
    • This defect is linked to impaired arachidonic acid uptake, not altered calcium influx.
    • The presence of platelet CD36 is critical for the inhibitory effect of arachidonic acid on aggregation, especially at low concentrations.

    Conclusions:

    • Platelet CD36 plays a vital role in facilitating arachidonic acid uptake, a key step in platelet aggregation.
    • CD36 deficiency leads to impaired platelet function due to defective arachidonic acid transport.
    • Specific genetic variations at codon 90 of CD36 significantly influence its surface expression and function.